Primary Category:
Treatment Protocols
Disease Category:
Chronic Myeloid Leukemia, Leukemia
Status:
Open
BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD
NCT#03516279
EA9171 is reopened to accrual with the implementation of Addendum 10, effective April 18, 2023
